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The cytokine IL-6 acts via a specific receptor complex that consists of the membrane-bound IL-6 receptor 
(mIL-6R) or the soluble IL-6 receptor (sIL-6R) and glycoprotein 130 (gp130). In this study, we investigated the 
role of IL-6R components in asthma. We observed increased levels of sIL-6R in the airways of patients with 
allergic asthma as compared to those in controls. In addition, local blockade of the sIL-6R in a murine model 
of late-phase asthma after OVA sensitization by gp130–fraction constant led to suppression of Th2 cells in 
the lung. By contrast, blockade of mIL-6R induced local expansion of Foxp3-positive CD4+CD25+ Tregs with 
increased immunosuppressive capacities. CD4+CD25+ but not CD4+CD25– lung T cells selectively expressed 
the IL-6R α chain and showed IL-6–dependent STAT-3 phosphorylation. Finally, in an in vivo transfer model 
of asthma in immunodeficient Rag1 mice, CD4+CD25+ T cells isolated from anti–IL-6R antibody–treated mice 
exhibited marked immunosuppressive and antiinflammatory functions. IL-6 signaling therefore controls the 
balance between effector cells and Tregs in the lung by means of different receptor components. Furthermore, 
inhibition of IL-6 signaling emerges as a novel molecular approach for the treatment of allergic asthma.
Introduction
Allergic asthma is a chronic inflammatory disease characterized by 
airway inflammation and airway hyperresponsiveness (AHR) that 
affects about 10% of the population in the US (1). The develop-
ment of allergic immune responses in asthma is mediated by CD4+ 
effector T cells producing Th2 cytokines (2–4). These Th2 cells and 
their signature cytokines, IL-4, IL-5, IL-9, and IL-13, are thought to 
play a key pathogenic role in asthma (5–8).
Although allergic asthma is associated with the presence of 
mucosal Th2 cells, it is not entirely clear which factors are respon-
sible for priming of T cells to differentiate into Th2 effector cells 
in this disease. However, it has been recently shown in experimen-
tal asthma that IL-4 produced by invariant natural killer T cells 
might be responsible for this priming (9). Another possibility is 
that, upon antigen exposure, the activation of APCs results in the 
release of factors which are responsible for the activation and dif-
ferentiation of T cells. In this respect, the cytokine IL-6 might be 
of interest, since it has been demonstrated that IL-6 derived from 
APCs is able to induce initial IL-4 production in naive CD4+ spleen 
T cells via activation of the transcription factor NFATc2, thereby 
polarizing these cells into Th2 cells (10–12).
IL-6 is a proinflammatory cytokine that plays a central role in 
host defense against infections and tissue injury (13–18). IL-6 elic-
its cellular actions by binding to the membrane-bound IL-6 recep-
tor (mIL-6R), then recruiting 2 membrane-spanning glycoprotein 
130 (gp130) molecules into tetra- or hexametric structures, thereby 
forming the active IL-6R complex. However, neither IL-6 nor IL-6R 
alone can bind or activate gp130. Homodimerization of the 2 gp130 
molecules leads to intracellular activation of the nonreceptor protein 
tyrosine kinases Src and JAK as well as members of the STAT family 
of transcription factors (19–23). While gp130 is expressed ubiqui-
tously, the expression of mIL-6R is restricted to the membrane of 
hepatocytes and hematopoietic cells. However, cells lacking mIL-6R 
can also respond to IL-6 via the soluble IL-6 receptor (sIL-6R), since 
the IL-6/sIL-6R complex can activate target cells expressing gp130 
in a process termed IL-6 trans-signaling (24–31). Interestingly, recent 
studies in peritonitis models suggest that such IL-6 trans-signaling is 
of crucial importance in the transition from acute to chronic phases 
of inflammatory processes (25).
In this study we delineate different roles for sIL-6R and mIL-6R in 
asthma. In fact, we found increased levels of sIL-6R in the airways 
of patients with allergic asthma as compared to those of controls. 
In addition, local blockade of sIL-6R in a murine model of late-
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phase asthma after OVA sensitization by gp130–fraction constant 
(gp130-Fc) led to suppression of Th2 cells in the lung. By contrast, 
local treatment in the lung with anti–IL-6R antibody induced Th1-
CD4+ cells as well as Foxp3-positive, IL-6R–positive CD4+CD25+ 
Tregs with immunosuppressive functions in the lung in vivo. Our 
results therefore demonstrate different roles for sIL-6R and mIL-6R 
in experimental asthma; sIL-6R regulates Th2 cell functions in 
CD4+CD25– T effector cells lacking the mIL-6R chain. By contrast, 
mIL-6R controls the cell fate at the beginning of T cell differentia-
tion by directing CD4+ naive cells toward Th2 pathways and inhibit-
ing Treg differentiation in the lung. Blockade of IL-6 signaling thus 
emerges as a promising approach for the treatment of Th2-depen-
dent inflammatory processes such as allergic asthma in humans.
Results
Increased levels of sIL-6R in the bronchoalveolar lavage fluid of patients 
with allergic asthma. Whereas IL-6 is known to be increased in 
bronchoalveolar lavage fluid (BALF) obtained from patients with 
allergic asthma after allergen challenge (32), diagnostic levels of 
sIL-6R in BALF have not been determined in this disease. To ana-
lyze levels of sIL-6R in asthma, we determined sIL-6R levels in BALF 
of patients with allergic asthma before and after allergen challenge. 
As shown in Figure 1A, baseline concen-
trations of sIL-6R in BALF of asthmatic 
patients before allergen challenge were 
significantly increased compared to those 
of control subjects. Furthermore, 24 hours 
after antigen challenge, sIL-6R concentra-
tions in BALF of asthmatics were increased 
as compared to baseline levels and signifi-
cantly higher as compared to those in BALF 
of control patients. A positive correlation 
(r = 0.90; P < 0.0001) was found between the 
number of CD4+ cells in BALF of asthmatic 
subjects after allergen challenge and BALF 
concentration of sIL-6R (Figure 1C). Spe-
cifically, sIL-6R levels positively correlated 
with the number of IL-5–producing CD4+ 
T cells (r = 0.91; P < 0.0001) (Figure 1D), the 
levels of IL-5 and IL-13 proteins (r = 0.90; 
P < 0.0001) (Figure 1, E and F, respectively), 
and, to a lesser extent, with the number of 
eosinophils (Figure 1B) (r = 0.60; P = 0.028) 
in BALF after allergen challenge. This sug-
gests a potential role for sIL-6R in control-
ling Th2 function in asthmatic subjects 
after allergen challenge.
Blockade of sIL-6R by use of gp130-Fc inhibits 
Th2 cytokine production in experimental asthma 
by downregulating GATA-3 levels. Asthma is 
characterized by increased infiltration of the 
airways with CD4+ Th2 cells, which produce 
signature cytokines such as IL-4, IL-5, and 
IL-13. Since the above data in humans sug-
gests a potential correlation between sIL-6R 
levels in BALF and Th2 cytokine production 
in asthma, we next analyzed Th2 cytokine 
levels in a model of experimental asthma 
upon blockade of sIL-6R function in vivo. 
Accordingly, we used a murine model of 
late-phase asthma induced by OVA sensitization and subsequent 
intranasal (i.n.) OVA challenge and determined Th2 cytokine pro-
duction in the lung upon specific blockade of sIL-6R using the chi-
meric protein gp130-Fc: a treatment that does not affect signaling 
via mIL-6R (24–32). Selective blockade of sIL-6R in the lung led to 
a significant downregulation of IL-4, IL-5, and IL-13 levels in BALF 
of OVA-sensitized mice as compared to that of OVA-sensitized 
and -challenged, untreated or IgG-treated control mice (Figure 2A, 
P = 0.03; Figure 2B, P = 0.006; Figure 2C, P = 0.00067). Since GATA-3 
is the master transcription factor regulating expression of the Th2 
cytokines IL-4, IL-5, and IL-13 in asthma (33, 34), we next analyzed 
GATA-3 expression by Western blot analysis and found that gp130-Fc 
treatment downregulated GATA-3 in the lungs of treated mice 
(Figure 2, D and E; P = 0.016 for OVA-treated versus saline-treated 
mice; P = 0.00056 for OVA/gp130-Fc–treated versus OVA-sensitized 
and -challenged, untreated mice). This was not accompanied by 
decreased GATA-3 expression per CD4+ lung T cell, as shown by RT-
PCR of 105 CD4+ lung T cells (Figure 2F). We therefore conclude 
that the decreased GATA-3 in the lung must be due to a decrease 
of total CD4+ T cells. Taken together, these data indicate that 
sIL-6R signaling controls the function of Th2 cells in experimental 
asthma. Moreover, treatment with anti–IL-6R antibody as well as 
Figure 1
sIL-6R is increased in BALF of asthmatic patients as compared to control subjects, and its lev-
els correlate with the number of IL-5–producing CD4+ T cells in BALF after allergen challenge. 
(A) sIL-6R was measured before (untreated) and 24 hours after allergen or saline challenge in 
control subjects (gray bars) or in subjects with asthma (black bars). In the asthmatic patients, 
sIL-6R levels were increased at baseline and were further increased after allergen challenge. 
*P < 0.05; ***P < 0.001. (B–D) In these patients, a positive correlation was found between the 
levels of sIL-6R and the number of CD4+ T cells (r = 0.9027; P < 0.0001) after allergen chal-
lenge (C). Furthermore, the value of sIL-6R positively correlated with the number of CD4+ T 
cells producing IL-5 in BALF (r = 0.9171; P = 0.0001) (D), while a lower correlation was found 
between sIL-6R and the number of eosinophils (Eos.) in BALF (r = 0.6059; P = 0.0282) (B). 
Furthermore, the value of sIL-6R in the airways of asthmatic subjects after allergen challenge 
correlates positively with the respective sIL-6R of IL-5 (E) and IL-13 (F) in BALF.
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gp130-Fc led to an upregulation of T-bet mRNA levels in the CD4+ 
lung cells of OVA-sensitized mice, indicating an upregulation of the 
Th1 phenotype in the lungs of treated mice (Figure 2F). The conse-
quence of these immunological changes was a downregulation of 
the total number of eosinophils in BALF of treated mice (Figure 3C; 
P = 0.0002 for anti–IL-6R antibody–treated mice and P = 0.0001 for 
gp130-Fc–treated mice).
Antiinflammatory mechanism of local treatment with anti–IL-6R anti-
bodies. It has been previously reported that pulmonary DCs secrete 
higher amounts of IL-6 as compared to spleen DCs. In addition, 
pulmonary DCs induce naive T cells to secrete IL-4, which induces 
a strong Th2 polarization in the lung (12). We then asked wheth-
er blockade of mIL-6R would decrease IL-4 and the other Th2 
cytokines. As shown in Figure 3A, blockade of IL-6R led to a specific 
downregulation of IL-4 (P = 0.05) and, at higher doses, IL-5 (Figure 
3B; P = 0.029) in the lungs of treated mice. This was accompanied by 
downregulation of the total number of eosinophils in BALF (Figure 
3C; P = 0.0002 for OVA-sensitized and -challenged, untreated mice 
versus OVA plus anti–IL-6R–treated mice) and total CD4+ lung cells 
(Figure 3, D and E; P = 0.05) in the airways of treated mice, indicat-
ing that blockade of mIL-6R interferes with early events during Th2 
differentiation rather than after Th2 cells have developed.
Local treatment with anti–IL-6R antibodies ameliorates AHR in OVA-
sensitized mice. Next we determined whether blockade of sIL-6R 
with gp130-Fc would affect allergic AHR and compared such 
effects with those observed following blockade of both mIL-6R 
and sIL-6R with anti–IL-6R antibodies. Accordingly, we subjected 
6 to 8 OVA-sensitized mice per group to i.n. treatment with the 
fusion protein gp130, anti–IL-6R antibodies, IgG control antibod-
ies, or saline and assessed AHR by invasive plethysmography after 
intravenous methacholine (MCh) challenge at day 28. As shown 
in Figure 4A, OVA-sensitized mice showed an increase in AHR 
compared with saline-treated control mice after challenge. Fur-
thermore, it was found that anti–IL-6R treatment (P = 0.049, as 
compared to IgG treatment; Figure 4A) reduced AHR more than 
gp130-Fc–treatment in OVA-sensitized mice, which indicates that 
anti–IL-6R antibody treatment has a beneficial effect on AHR.
Anti–IL-6R antibody treatment induces IL-10 and IFN-γ production by 
lung CD4+ T lymphocytes. We next analyzed cytokines in BALF and 
found that treatment with anti–IL-6R antibodies but not gp130-Fc 
was associated with significant induction of IFN-γ (P = 0.048) and 
IL-10 levels (P = 0.020) in BALF of OVA-sensitized mice (Figure 4, 
B and C, respectively). These results are consistent with previous 
reports showing enhanced ability of pulmonary DCs isolated from 
IL-6–/– mice to induce a Th1 response (12). In fact, we found that a 
blockade of IL-6R led to an upregulation of T-bet, the Th1 signa-
ture transcription factor in lung CD4+ cells (Figure 2F).
Further, in isolated CD4+ T cells from the lungs of treated or 
untreated, OVA-sensitized mice, after overnight cell culture, 
Cytometric Bead Array (CBA; BD Biosciences — Clontech) analysis 
was performed, using CD4+ T cell supernatants. It was found that 
CD4+ T cells isolated from the lungs of anti–IL-6R, antibody–treated 
Figure 2
Local blockade of sIL-6R by gp130-Fc downregulates IL-4, IL-5, and IL-13 levels and reduces GATA-3 expression in experimental asthma. 
BALB/c mice were sensitized and challenged with OVA whereas control mice were given saline. Some OVA-sensitized mice received additional 
treatment with gp130-Fc to block sIL-6R function in vivo, as indicated. gp130-Fc treatment was associated with a significant decrease in IL-4 (A), 
IL-5 (B), and IL-13 (C) levels in BALF of OVA-sensitized mice. *P < 0.05; **P < 0.01; ***P < 0.001. Data represent mean values ± SEM from 5 
mice per group. (D) Total lung proteins were isolated from gp130-Fc–treated mice and untreated control mice at day 28 and analyzed by Western 
blot analysis after immunoblotting with a monoclonal antibody directed against GATA-3. Furthermore, ERK2 expression was determined on the 
same blot after membrane stripping and incubation with an anti–ERK-2 antibody. Each lane in the Western blot was loaded with 50 μg proteins 
isolated from different mice (saline, n = 4; OVA, n = 5; OVA + gp130-Fc, n = 5). Quantification of Western blots by densitometry is reported in E 
and shows decreased GATA-3 expression after i.n. delivery of gp130-Fc in OVA-sensitized and -challenged mice (*P < 0.05; ***P = 0.00056). (F) 
RT-PCR for GATA-3 and T-bet in 105 lung CD4+ T cells per group after total RNA extraction. Both anti–IL-6R antibody and gp130-Fc treatment 
led to upregulation of T-bet, while GATA-3 remained unchanged in lung OVA-specific CD4+ T cells.
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(Figure 5, A and B) but not gp130-Fc–treated mice (Figure 5, C and 
D; as assessed by ELISA) secreted significantly increased amounts 
of IL-10 (Figure 5, A and B, for anti–IL-6R antibodies, P = 0.023; 
Figure 4C for gp130-Fc–treated mice) and IFN-γ (Figure 5, A and 
B, for anti–IL-6R antibodies, P = 0.013; Figure 5D for gp130-Fc–
treated mice) after T cell receptor–dependent stimulation, as com-
pared to IgG-treated or OVA-sensitized and -challenged, untreated 
mice. In contrast, levels of the Th2 type chemokine monocyte 
chemoattractant protein-1 (MCP-1) were not upregulated upon 
anti–IL-6R antibody treatment (Figure 5A). Taken together, these 
data suggest that blockade of mIL-6R causes induction of IL-10 and 
IFN-γ production by lung CD4+ T lymphocytes.
Figure 3
Antiinflammatory mechanism of local treatment with anti–IL-6R antibodies. Blockade of IL-6R led to a downregulation of IL-4 (P = 0.05) (A), 
and, at higher doses (100 μg/day), of IL-5 (P = 0.029) (B) in the lungs of treated mice. These findings were accompanied by downregulation of 
the total number of eosinophils (P = 0.0002) in BALF (C) and CD4+ cells (P = 0.05) in the airways of treated mice (D and E). (D) CD4+ lung cells 
were stained by using monoclonal anti-CD4 antibodies (BD), and immunohistochemistry was performed as previously described (34). Pictures 
were taken with an Olympus inverted microscope connected to a digital camera. Original magnification, ×400. (E) The number of CD4+ lung cells 
obtained from 1 lung after CD4 isolation is reported for different groups. *P < 0.05; ***P < 0.001.
Figure 4
Blockade of mIL-6R through i.n. application of anti–IL-6R antibodies 
ameliorates AHR and induces IFN-γ and IL-10 levels in BALF in a 
mouse model of asthma after OVA sensitization. (A) Eight to 10 BALB/
c mice per group were sensitized to OVA-alum (OVA-sensitized mice) 
followed by local treatment with OVA alone or treatment with OVA 
plus either gp130-Fc, IgG, or anti–IL-6R antibody. Control mice were 
sensitized with saline-alum and exposed to saline aerosol (saline). 
Transpulmonary resistance was performed 24 hours after the last local 
treatment in all mice, as specified in Methods. Dose-response curves 
to MCh were obtained after administering indicated doses of intrave-
nous MCh. OVA-sensitized mice reacted with an increase of airway 
resistance at low doses of MCh as compared to that of mice given 
saline. Anti–IL-6R–treated, OVA-sensitized mice were more protected 
from the development of AHR compared to untreated (P = 0.049) or 
IgG-treated, OVA-sensitized mice. Moreover, blockade of sIL-6R by 
gp130-Fc was less effective compared to anti–IL-6R antibody treat-
ment. (B and C) Local anti–IL-6R antibody treatment induced signifi-
cant release of IFN-γ (P = 0.048) (B) and IL-10 (P = 0.020) (C) in BALF 
of OVA-senstitized mice as compared to untreated, OVA-sensitized 
mice (5 < n < 15). Mean values ± SEM are shown. *P < 0.05.
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Increased release of IL-10 in Foxp3+ CD4+CD25+ Tregs isolated from 
the lungs of anti–IL-6R–treated mice. Since IL-10 is a cytokine with 
potent antiinflammatory activities that is produced by subsets of 
Tregs (35–37), we next determined whether CD4+CD25+ T cells 
from the lung produce IL-10 upon anti–IL-6R antibody treat-
ment. Accordingly, we separated CD4+CD25+ lung T cells from 
CD4+CD25– lung T cells and analyzed cytokine release. As shown 
in Figure 6B, CD4+CD25+ T cells isolated from anti–IL-6R anti-
body–treated, OVA-sensitized mice released significantly increased 
amounts of IL-10 per cell as compared to CD4+CD25+ T cells iso-
lated from OVA-sensitized and -challenged, untreated (P = 0.0034) 
or IgG-treated mice. In addition to IL-10, CD4+CD25+ lung cells 
also produced TGF-β, suggesting their potential regulatory activity 
(Figure 6A; TGF-β released from CD4+CD25– versus CD4+CD25+ 
lung cells; P = 0.019 for anti–IL-6R antibody–treated mice; 
P = 0.004 for OVA-sensitized and -challenged, untreated mice). In 
contrast, CD4+CD25– lung T cells produced little or no IL-10 (Fig-
ure 6B), although they did produce TGF-β (Figure 6A). Moreover, 
CD4+CD25+ as well as CD4+CD25– cells isolated from the lungs of 
gp130-Fc–treated mice released significantly less TGF-β as com-
pared to those isolated from the lungs of untreated mice (P = 0.05 
for CD4+CD25+ and P = 0.0035 for CD4+CD25–), indicating a lower 
T regulatory inductive capability of the lung effector T cells iso-
lated from gp130-Fc–treated mice (38). Furthermore, we analyzed 
IFN-γ production in CD4+CD25+ and CD4+CD25– cells and found 
that both cell populations released IFN-γ. However, CD4+CD25+ 
lung cells isolated from gp130-Fc–treated mice released less IFN-γ 
as compared to CD4+CD25+ cells isolated from OVA-sensitized 
and -challenged, untreated mice (Figure 6C).
Moreover, as CD4+CD25+ Tregs in the lung are known to spe-
cifically express the forkhead family member transcription factor 
Foxp3, we finally determined Foxp3 expression in CD4+CD25+ 
lung T cells (39–43). It was found that CD4+CD25+ lung T cells 
but not CD4+CD25– lung T cells express Foxp3 (Figure 6D). Fur-
thermore, anti–IL-6R antibody treatment but not gp130-Fc treat-
ment led to an upregulation of Foxp3 expression in CD4+CD25+ 
T cells, as assessed by real-time PCR (Figure 6E; P = 0.04 for 
CD4+CD25+ cells isolated from the lungs of OVA-sensitized and 
-challenged, untreated versus anti–IL-6R antibody–treated mice). 
These results indicated specific activation of Foxp3-expressing 
CD4+CD25+ lung Tregs releasing IL-10 and TGF-β, especially 
after local treatment with anti–IL-6R antibodies.
Expansion and augmented regulatory function of CD4+CD25+ lung 
Tregs upon local anti–IL-6R antibody treatment. To determine wheth-
er anti–IL-6R antibody treatment modulates the expansion and 
immunosuppressive function of CD4+CD25+ lung Tregs, we next 
analyzed the number of CD4+CD25+ cells in the lungs of untreat-
ed and treated OVA-sensitized mice by cell sorting. As shown in 
Figure 7A, the number of CD4+CD25+ Tregs was increased signifi-
cantly in the lungs upon local anti–IL-6R antibody treatment but 
not upon gp130-Fc treatment in OVA-sensitized mice (P = 0.034). 
In contrast, systemic blockade of IL-6R function before sensi-
tization with OVA at day 0 by i.p. administration of anti–IL-6R 
antibody treatment did not increase the number of CD4+CD25+ 
Tregs in the lungs of OVA-sensitized mice. Furthermore, IL-6R 
blockade was accompanied by a significant increase in IL-6 levels 
in BALF of treated mice (Figure 7B; P = 0.02 OVA-treated mice 
versus i.p. anti–IL-6R antibody–treated mice), which suggests that 
i.p. application of anti–IL-6R antibodies leads to a negative feed-
back mechanism that increases IL-6 levels.
The above data demonstrate that local rather than systemic block-
ade of IL-6 signal transduction leads to an expansion of CD4+CD25+ 
Figure 5
IL-10–producing CD4+ T cells in the lungs of 
anti–IL-6R antibody–treated mice. (A and B) CD4+ 
T cells were isolated from the lung of treated or 
untreated mice and cultured overnight in the pres-
ence of anti-CD3 antibodies. CBA was performed 
on the CD4+ T cell supernatants. CD4+ T cells iso-
lated from the lung of anti–IL-6R antibody–treated 
mice secreted increased amounts of IL-10 and 
IFN-γ as compared to those of OVA-sensitized 
and -challenged, untreated or IgG-treated mice 
(P = 0.023 and P = 0.013 for IL-10 and IFN-γ, 
respectively). Levels of the Th2-type chemokine 
MCP-1 were not upregulated upon anti–IL-6R anti-
body treatment, however. (C and D) By contrast, 
lung CD4+ cells isolated from mice treated i.n. with 
gp130-Fc did not show changes either in IL-10 (C) 
or IFN-γ production (D).
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Tregs in the lung. We next analyzed the regulatory potential of these 
cells in coculture experiments with spleen target cells. In these stud-
ies, CD4+CD25+ lung T cells were incubated with CFSE-labeled, 
primary CD4+ spleen T cells in the presence of antigen-present-
ing cells and anti-CD3 antibodies. As shown in Figure 7, C and D, 
CD4+CD25+ lung T cells isolated from locally anti–IL-6R–treated, 
OVA-sensitized mice exhibited an increased suppressive capacity 
against spleen target cells as compared to CD4+CD25+ Tregs derived 
from untreated, OVA-sensitized mice (P = 0.033), as shown by the 
decreased number of CFSE+ cells that could be recovered at day 4 
either at the fifth mitosis (M5) or at M6. Taken together, these data 
suggest that local blockade of IL-6 signal transduction in the lung 
results in both expansion and augmentation of immunosuppressive 
capacities of CD4+CD25+ Tregs.
Selective expression of the IL-6R α chain in lung CD4+CD25+ T lympho-
cytes. Since the above data suggested that IL-6 signal transduction 
in CD4+CD25+ lung Tregs involves signaling via mIL-6R rather 
than sIL-6R, we determined in subsequent studies the expression 
of mIL-6R mRNA in such cells. This approach was important in 
understanding whether IL-6 would act directly on CD4+CD25+ 
Tregs via mIL-6R. Interestingly, we found that the IL-6R α chain 
is selectively expressed on CD4+CD25+ lung T cells but not on 
CD4+CD25– lung T cells, which suggests a direct effect of IL-6 via 
mIL-6R on CD4+CD25+ Tregs (Figure 7E).
Anti–IL-6R antibodies antagonize IL-6–induced STAT-3 phosphorylation 
in CD4+CD25+ Tregs. To start to investigate the mechanism of action 
of IL-6 on CD4+CD25+ Treg function, we incubated CD4+CD25+ 
Tregs with IL-6 alone or with anti–IL-6R antibodies for 36 min-
utes. IL-6 induced phosphorylation and nuclear translocation of 
STAT-3 (44) in CD4+CD25+ cells, which could be reversed by coin-
cubation with anti–IL-6R antibodies (Figure 7F), demonstrating 
functional activation of IL-6R in CD4+CD25+ cells.
CD4+CD25+ T cells from anti–IL-6R–treated mice inhibit CD4+CD25– T 
cell–induced inflammation in an adoptive transfer model in Rag1 knockout 
mice. In a final series of experiments, we aimed at characterizing 
the immunosuppressive properties of CD4+CD25+ T lymphocytes 
upon anti–IL-6R antibody treatment in vivo. To demonstrate the 
functional importance of CD4+CD25+ Tregs in asthma, we first iso-
lated CD4+CD25+ T cells and CD4+CD25– T cells from the spleens 
of OVA-sensitized mice treated i.n. during the challenge phase with 
either anti–IL-6R or IgG control antibodies. We then cotransferred 
i.p. CD4+CD25+ T cells from either IgG or anti–IL-6R antibody–
treated mice or CD4+CD25– T cells from IgG-treated mice together 
with equal numbers of CFSE-labeled CD4+CD25– T cells from OVA-
sensitized mice into Rag1 knockout mice. As shown in Figure 8H, 
Rag1–/– mice receiving CD4+CD25– T cells showed CFSE positive cells 
in the lung, indicating homing of the labeled T cells. Moreover, mice 
cotransferred with CD4+CD25+ T cells from IgG-treated mice showed 
a marked decrease in the number of CFSE-positive cells (Figure 8, 
G–I) in the lung, suggesting inhibition of effector T cell prolifera-
tion by CD4+CD25+ T cells (Figure 8G). Moreover, CD4+CD25+ cells 
isolated from anti–IL-6R antibody–treated mice showed increased 
immunosuppressive capability as compared to those isolated from 
IgG-treated mice (P = 0.00040). Such inhibition was accompanied by 
reduced levels of IL-4 in BALF of reconstituted Rag1 knockout mice 
(data not shown). Histologically, Rag1–/– mice receiving CD4+CD25+ 
T cells were protected from the development of airway inflammation 
(Figure 8, A–F; 891 ± 1070 or 305 cells/mm2 for CD4+CD25– recon-
stituted mice; –231 ± 682 or 179 cells/mm2 for CD4+CD25+ IgG-
treated and CD4+CD25– IgG-treated mice; 88 ± 407 or 162 cells/mm2 
Figure 6
Increased release of IL-10 from Foxp3+ CD4+CD25+ 
Tregs isolated from the lungs of anti–IL-6R–treated mice. 
CD4+CD25+ T cells and CD4+CD25– T cells were isolated 
from lung cells in the different experimental groups, after 
which cytokine production was analyzed. The purity of the 
CD4+CD25+ cell population was 95–98% as determined by 
FACS analysis during cell sorting. (A–C) Lung CD4+CD25+ 
T cells isolated from OVA-sensitized, anti–IL-6R anti-
body–treated mice released increased amounts of IL-10 
(B) per cell as compared to CD4+CD25+ T cells from OVA-
sensitized and -challenged, untreated or OVA-sensitized, 
IgG-treated mice. In contrast, lung CD4+CD25– T cells pro-
duced little IL-10 (B) but more TGF-β (A) and some IFN-γ 
(C). n = 6. By contrast, CD4+CD25+ isolated from gp130-
Fc–treated mice released less IL-10 (B), IFN-γ (C), and 
TGF-β (A), while the CD4+CD25– isolated from the same 
mice released the same amount of IL-10 (B) and less 
TGF-β (A). (D) Expression of Foxp3 on CD4+CD25+ lung 
T cells upon anti–IL-6R antibody treatment. CD4+CD25+ 
and CD4+CD25– lung T cells from untreated or anti–IL-6R 
antibody–treated, OVA-sensitized mice were separated as 
described above. This was followed by RNA extraction and 
analysis of Foxp3 or β-actin expression by RT-PCR. (E) 
Real-time PCR for Foxp3 in CD4+CD25+ and CD4+CD25– 
cells is reported as the ratio of Foxp3 to HGPRT. Anti– 
IL-6R antibody treatment led to a significant upregulation 
of Foxp3 as compared to OVA treatment. This experiment 
was performed 3 times in duplicate. *P < 0.05; **P < 0.01.
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for CD4+CD25– and anti–IL-6R antibody–treated mice). These data 
indicate an antiinflammatory effect similar to that of CD4+CD25+ 
cells derived from either IgG-treated or anti–IL-6R antibody–treat-
ed mice. Taken together, these results indicate that the number of 
CD4+CD25+ T cells is important in inducing immunosuppressive 
functions on allergic airway inflammation under in vivo conditions.
Discussion
Although previous studies demonstrated increased production 
of IL-6 in patients with allergic asthma as compared to that in 
controls (32), it remained unclear whether IL-6 signaling plays 
a role in the effector phase of allergic airway inflammation and 
whether antagonizing the function of IL-6 can be used for the 
therapy of allergic airway inflammation and AHR. Furthermore, 
the potential mechanisms of action of such therapy remained to 
be elucidated. Here we demonstrate that IL-6 signaling controls 
the balance between effector T cells and Tregs in experimental 
asthma by means of different receptor components. Specifically, 
our data suggest that IL-6 trans-signaling via sIL-6R supports 
Th2 lung T cell cytokine production, whereas IL-6 signaling via 
Figure 7
Increased number and augmented immunosuppressive function of CD4+CD25+ T cells in the lungs of anti–IL-6R–treated, OVA-sensitized mice. 
(A) i.n. but not i.p. anti–IL-6R antibody treatment after OVA sensitization and challenge led to an induction of CD4+CD25+ T cell number in the 
lung (*P = 0.057). (B) IL-6 levels were increased in BALF of OVA-sensitized mice as compared to those of saline-treated mice. i.p. but not i.n. 
injection of anti–IL-6R antibodies led to a further increase of IL-6 in the airways. (C) CD4+CD25+ T cells isolated from the lungs of anti–IL-6R 
antibody–treated (i.n.) mice inhibited proliferation of CFSE-labeled target CD4+ spleen T cells more efficiently compared to CD4+CD25+ T 
cells isolated from the lungs of OVA-sensitized and -challenged, untreated mice. Mean values ± SEM; n = 5 mice per group; *P < 0.05. (D) 
Histograms of a representative cell population of CD4+ spleen cells labeled with CFSE and coincubated for 4 days with either CD4+CD25+ or 
CD4+CD25– cells isolated from the lungs of different groups. Percentages indicate the number of spleen CD4+/CFSE-labeled cells at day 4 (M1, 
20 hours). (E) RT-PCR for the IL-6R α chain shows selective expression on Foxp3+ CD4+CD25+ lung T cells but not CD4+CD25– lung T cells. 
One representative experiment out of 3 is shown. (F) phospho–STAT-3 (pSTAT3) immunostaining in CD4+CD25+ cells. Spleen CD4+CD25+ T 
cells were incubated either with medium alone (left panel), with 20 ng/ml of IL-6 (middle panel), or with IL-6 (20 ng/ml) and anti–IL-6R antibodies 
(10 μg/ml) (right panel). Magnification, ×200.
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mIL-6R suppresses the development and functional activity of 
Foxp3+ CD4+CD25+ Tregs in the lung and induces the early devel-
opment of lung CD4+ naive T cells via IL-4. Consistent with this 
concept, blockade of mIL-6R signaling induced expansion and 
immunosuppressive capacities of CD4+CD25+ lung Tregs in vivo 
and induced CD4+ IFN-γ–producing cells in the lung, ameliorat-
ing AHR in experimental asthma. These Tregs are similar to those 
previously described in the spleen (45, 46). Although, in our study, 
Tregs isolated from the lung, in contrast to those isolated from the 
spleen, produced IFN-γ in addition to TGF-β and IL-10, we think 
that additional experiments are required to define whether 2 dif-
ferent populations of Tregs are present in the CD4+CD25+ lung 
Treg population used in this study.
IL-6 elicits cellular actions by binding to the membrane-bound 
α chain of its receptor (mIL-6R α chain). This event is followed 
by recruitment of 2 membrane-spanning gp130 molecules into 
tetra- or hexametric structures, thereby forming the active IL-6R 
complex. In addition, a soluble form of the mIL-6R α chain 
can mediate signal transduction in cells lacking mIL-6R by a 
mechanism called trans-signaling. In both cases, binding of IL-6 
to the α chain leads to homodimerization of the 2 gp130 mol-
ecules and intracellular activation of Src and JAK, which in turn 
phosphorylate STAT3 (19–23) and activate IL-6 target genes. The 
functional importance of IL-6 signaling in T lymphocytes has been 
underlined by the finding that such signaling augments T cell acti-
vation and T helper 2 cell polarization in vitro and in vivo.
In initial studies on IL-6 signaling in asthma, we 
observed an increased production of sIL-6R in BALF of 
patients with allergic asthma at baseline as compared 
to that of control subjects and a further increase after 
allergen challenge. Interestingly, sIL-6R levels strongly 
correlated with the number of CD4+/IL-5–producing 
cells along with IL-5 and IL-13 levels in BALF of asth-
matics after allergen challenge, suggesting that sIL-6R 
levels contribute to Th2 cell development in asthma. 
To further extend the above findings, we took advantage of a model 
of asthma in mice associated with Th2-mediated airway inflamma-
tion and AHR (28). To understand the immunopathological role 
of IL-6 in this model, during the challenge phase, we selectively 
blocked either sIL-6R via gp130-Fc or sIL-6R plus mIL-6R via 
anti–IL-6R antibodies. In the first therapeutic approach, we used 
a chimeric gp130-Fc fusion protein that competes with gp130 and 
thereby specifically blocks IL-6 trans-signaling. Consistent with the 
above data in humans, it was found that specific suppression of 
sIL-6R signaling via administration of gp130-Fc suppresses Th2 T 
cell development and subsequent production of effector cytokines 
in experimental asthma in vivo. Specifically, blockade of sIL-6R sig-
naling in experimental asthma led to downregulation of the master 
transcription factor of Th2 cells, GATA-3, and suppression of IL-4, 
IL-5, and IL-13 production. Collectively, these data indicate an 
important role for IL-6 trans-signaling via sIL-6R in controlling Th2 
T cell function in asthma.
In contrast to gp130-Fc treatment, local administration of anti– 
IL-6R antibodies led to downregulation of IL-4 and induction of IFN-γ 
production by CD4+ lung T cells as well as amelioration of AHR, sug-
gesting the existence of important IL-6–dependent but sIL-6R–inde-
pendent signaling events at the beginning of Th2 differentiation in 
the lung in experimental asthma. These results are consistent with a 
Th2-promoting potential of pulmonary DCs due to the inhibition 
of Th1 differentiation caused by IL-6 production (12). Moreover, we 
identified mIL-6R as being responsible for the Th1 inhibition, since 
Figure 8
CD4+CD25+ T cells from OVA-sensitized mice can 
inhibit CD4+CD25– T cell–induced experimental asthma 
in Rag1–/– mice. (A–F) Cotransfer of CD4+CD25+ and 
CD4+CD25– spleen T cells into Rag1–/– mice. CD4+CD25+ 
and CD4+CD25– T cells were isolated from the spleens 
of OVA-sensitized and -challenged mice given IgG-
control antibodies or anti–IL-6R antibodies. CFSE-
labeled CD4+CD25– spleen T cells from OVA-sensitized 
mice (5 × 105; CSFE-labeled indicated with asterisks) 
were cotransferred i.p. with either 5 × 105 unlabeled 
CD4+CD25– T cells (A and D) or CD4+CD25+ T cells (B, 
C, E, and F) into immunocompromised Rag1 knockout 
mice. Cotransfer of CD4+CD25+ T cells from anti–IL-6R– 
treated (C and F) or IgG-treated (B and E) mice sup-
pressed allergic airway inflammation induced by transfer 
of CD4+CD25– T cells from OVA-sensitized mice. Mag-
nification, ×100 (A–C), ×400 (D–F). Mice receiving only 
CD4+CD25– T cells showed CFSE-positive cells in the 
lung (H), whereas mice receiving CD4+CD25+ T cells as 
well showed a marked decrease in the number of CFSE-
positive cells (G and I), suggesting a CD4+CD25+ T cell–
mediated suppression of effector CD4+CD25– T cell pro-
liferation. Results in G were obtained by calculating the 
average number of CFSE-positive cells per high power 
field (HPF) (n = 30). ***P = 0.001.
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blockade of the IL-6R with antibodies significantly induced IFN-γ in 
the airways. By contrast, sIL-6R might control the number of Th2 
cells, since IFN-γ was not induced by this treatment (Figure 5C). We 
further demonstrated that anti–IL-6R antibody treatment led to the 
simultaneous increase of CD4+CD25+ lung T cells releasing IL-10. 
Such cells were increased in number in the airways of mice given 
anti–IL-6R antibodies locally, suggesting that mIL-6R signaling con-
trols expansion of CD4+CD25+ lung Tregs. This concept was under-
lined by the finding that CD4+CD25+ but not CD4+CD25– lung T 
cells expressed mRNA for mIL-6R. Thus, whereas CD4+CD25+ lung 
T cells are susceptible to signaling via mIL-6R, CD4+CD25– effector 
T cells in the lung may respond to sIL-6R signaling only.
CD4+CD25+ Tregs are known to regulate innate and adaptive 
immune responses and to possess potent antiinflammatory capac-
ity in autoimmune and chronic inflammatory diseases such as 
experimental autoimmune encephalitis, diabetes, and allergy in 
vivo (42–44). Although such Tregs are known to be produced in 
the thymus after birth, recent evidence suggests that they can also 
develop in the lung (45). However, the signaling pathways that con-
trol Treg development in the lung are still poorly understood. Our 
data provide evidence for a key role of IL-6 signaling via mIL-6R 
in preventing Treg responses in experimental asthma. Specifically, 
we found that local application of anti–IL-6R antibodies leads to 
expansion of Foxp3+ CD4+CD25+ lung T cells (39–46), producing 
IL-10. Thus, signaling via mIL-6R present on T cells apparently sup-
presses the function of CD4+CD25+ Tregs in the lung. In addition, 
we demonstrate that IL-6R is functionally active in CD4+CD25+ 
T cells, since we have shown phosphorylation and activation of 
STAT-3 upon culture of these cells with IL-6, which is inhibited by 
anti–IL-6R antibody coincubation. These data extend other studies 
showing that IL-6 production by spleen DCs enhances effector T 
cell responses by overcoming CD4+CD25+ Treg suppression (37). 
However, our data suggest that this process occurs in the periph-
eral immune system in the lung in vivo and involves signaling via 
mIL-6R. The functional relevance of this concept for asthma was 
underlined by adoptive transfer studies in which CD4+CD25+ 
spleen T cells were able to suppress CD4+CD25– T cell–induced 
allergic airway inflammation in Rag1 knockout mice.
In summary, IL-6 signaling in the lung tightly controls the critical 
balance between effector and Treg function in the lung via differ-
ential signaling events involving sIL-6R and mIL-6R, respectively. 
Inhibition of IL-6 signaling results in beneficial effects in experi-
mental asthma by simultaneously suppressing Th2 cell develop-
ment via sIL-6R signaling and skewing naive CD4+ cells to a Th1 
pathway and/or expanding Tregs via mIL-6R signaling. Although 
these data are obtained from an experimental model of asthma, 
they suggest a potential therapeutic utility of antibodies against 
the IL-6R as a novel molecular approach for the induction of local 
T regulatory responses in patients with allergic asthma.
Methods
Patients with allergic asthma. Nine healthy volunteers and 14 patients with 
mild asthma participated in the study. The subject characteristics are 
described in Table 1. All patients had mild allergic asthma as defined in the 
Table 1
Clinical characteristics of the study subjects
 Age Sex FEV1 % PC20FEV1 IgE  Allergen  Allergen 
    mg/ml kU/l sensitivityA provocationB
Controls 33 F 103 10.2 62 – –
 32 M 95 11.9 5 – –
 23 M 103 10.5 52 – –
 27 M 101 20.0 7 – –
 23 M 104 25.4 7 – 0.1 μg gp
 25 M 108 11.9 3 – 0.1 μg gp
 24 M 103 11.3 9 – 0.1 μg gp
 28 M 96 16.1 8 – 0.6 μg Dp
 33 F 104 20.1 8 – 0.6 μg Dp
mean ± SEM 27.6 ± 1.4 2F/7M 102 ± 1 15.3 ± 1.8 17.9 ± 7.5  
Asthmatics 24 F 106 11.2 50 gp, hp, tp, c 0.01 μg gp
 22 M 91 12.4 310 gp, hp, Al, c 0.1 μg gp
 29 M 101 5.2 390 gp, Dp, Df, d 0.1 μg gp
 22 F 100 5.6 415 gp, tp, Al, Cl, c 0.01 μg gp
 27 M 109 2.9 323 gp, hp, tp, Al 0.1 μg gp
 24 F 90 2.6 728 gp, hp, tp, Dp, Df, c 0.6 μg Dp
 28 M 78 1.5 64 gp, hp, tp, Dp, Df, c 0.01 μg gp
 28 M 99 8.4 110 gp, tp, Al 0.1 μg gp
 26 M 96 3.6 73 gp, Al, c 0.1 μg gp
 24 M 90 8.5 168 gp, tp, Dp, Al, c 0.1 μg gp
 26 M 119 4.1 194 gp, hp, Dp, Df, c 0.1 μg gp
 23 F 79 0.5 96 gp, Dp, Df, K 0.1 μg gp
 22 M 115 13.0 40 tp, Dp, Df, c 0.6 μg Dp
 28 F 109 1.0 78 gp, tp, Dp, Df, Al, Cl, c 0.1 μg gp
mean ± SEM 25.2 ± 0.7 5F/9M 98.7 ± 3.3 5.8 ± 1.1C 217 ± 52.5C  
AAllergen sensitivity was determined by skin-prick test. gp, mixed grass pollen (Dac g5, Fes p5, Lol p5, Phl p5, Poa p5); hp, mixed herb pollen; tp, mixed 
tree pollen; Dp, Dermatophagoides pteronyssinus (Der p1, Der p2); Df, Dermatophagoides farinae; Al, Alternaria; Cl, Cladosporia; c, cat fur; d, dog hair. 
BAllergen provocation was performed with either gp or Dp. CP < 0.01 compared to controls. kU/l, kilo units per liter.
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(47). Subjects with asthma met the American Thoracic Society criteria for 
the diagnosis of asthma. They had histories of intermittent wheezing with 
reversible airflow obstruction, and asthma had previously been diagnosed 
by independent physicians. Each patient had a positive skin-prick test, 
defined as a greater than 4 mm diameter skin wheal response to 1 or more 
of 8 common allergens (Dermatophagoides pteronyssinus, Dermatophagoides fari-
nae, mixed grass pollen, mixed tree pollen, dog hair, feather, cat fur, Alter-
naria; allergen extractions from ALK-Abelló). The allergen extract used for 
segmental allergen challenge was the one which produced the largest wheal 
response on skin-prick testing, and the chosen concentration was one-tenth 
the dilution in saline that elicited a 3 mm diameter skin wheal response. 
Bronchial hyperresponsiveness and concentration of histamine producing 
a 20% fall in forced expiratory volume in 1 second (PC20FEV1) were deter-
mined as described (48). Patients were using only salbutamol when required 
for relief of symptoms. None was treated with corticosteroids, sodium cro-
moglycate, theophylline, or antileukotriens. The controls had no history 
of allergic or other diseases and had negative skin-prick tests, normal IgE 
(≤ 100 IU/ml), normal lung function tests, and no bronchial hyperrespon-
siveness (PC20FEV1 > 8 mg/ml). All study subjects were nonsmokers, and no 
subject had experienced acute bronchitis within 4 weeks prior to the inves-
tigations. All patients gave their written consent after being fully informed 
about the purpose and nature of the studies, which were approved by the 
Ethical Committee of Hannover Medical School.
Segmental allergen challenge. Segmental allergen challenge was performed 
as previously described (48). Briefly, all subjects (14 patients with mild 
asthma and 9 controls) received nebulized salbutamol (1.25 mg), atropine 
(0.5 mg s.c.), and midazolam (2–8 mg i.v.) prior to bronchoscopy. The bron-
choscope (P30; Olympus) was wedged into the inferior lingular bronchus, 
and a bronchoalveolar lavage (BAL) was performed with 5 × 20 ml sterile 
saline. The instrument was passed into the superior lingular bronchus, 
and 10 ml saline solution was instilled as a control challenge. Finally, the 
bronchoscope was passed to the medial segment of the middle lobe, and 10 
ml allergen solution was instilled. After 24 hours, subjects (all asthmatics 
and 5 controls) were bronchoscoped again with the same premedication, 
and the superior lingular bronchus and the medial middle bronchus were 
lavaged with 100 ml saline. BALF samples were filtered through a 100 μm 
filter and centrifuged, and the supernatant was stored at –80°C. Differen-
tial cell counts were performed from cytospin slides with 300 cells per slide 
being counted after staining with May-Grünwald-Giemsa stain.
Flow cytometric detection of intracellular cytokines and ELISA in BALF T cells. 
Intracellular cytokine detection of BALF-derived T cells was performed 
as previously described (49). Briefly, BALF cells isolated from 11 patients 
were resuspended in RPMI 1640 supplemented with 10% fetal calf serum 
(Biochrom AG) (1 × 106 cells/ml). Cells were cultured in 24-well flat-bot-
tom plates (Nunc) and stimulated with phorbol 12-myristate 13-acetate 
(PMA) (10 ng/ml) and ionomycin (1 μM) in the presence of monensin (2.5 
μM). After incubation for 4 hours at 37°C in a humidified atmosphere (5% 
CO2), cells were washed in PBS, and half of the cells were fixed in 1 ml 4% 
ice-cold paraformaldehyde (Riedel-de Haën) for 10 minutes. After a further 
wash in PBS, these cells were resuspended in 100 μl portions with saponin 
buffer and 0.01 M N-2-hydroxyethylpiperazine-N′-ethane sulfonic acid 
buffer (SERVA Electrophoresis). Anti-CD4+ FITC (1 mg/ml; Medac Inter-
national) and PE-labeled antibodies against IFN-γ or IL-5 (10 ml, dilution 
1:30; BD Biosciences — Pharmingen) were added to the cell suspension and 
incubated for 30 minutes in the dark. Nonspecific FITC-PE–labeled anti-
bodies (BD; Medac International) were used as controls. Flow cytometric 
analysis was performed with scatter gates on lymphocyte fractions, using a 
flow cytometer (FACSCalibur; BD). The human ELISA-kits (Duo-sets) for 
IL-5 and IL-13 were purchased from R&D Systems.
Allergen sensitization and challenge and anti–IL-6R antibody treatment. Female 
BALB/c mice (6–8 weeks of age) were maintained under specific pathogen-
free conditions and received i.p. injections of 100 μg OVA (Calbiochem) com-
plexed with alum (Sigma-Aldrich) on days 0 and 14, as previously described 
(24, 50). On days 25, 26, and 27, mice underwent anesthesia with avertine 
(1 mg tribromethanol/ml t-amylalcohol; 2.5% in PBS) before receiving 50 
μg OVA in saline. Treated mice received 50 μg of anti–IL-6R antibodies. 
Control animals received i.p. saline complexed with alum on days 0 and 14 
and an i.n. dose of 50 μl saline on days 25, 26, and 27 (24, 50).
To assess the role of IL-6 on airway inflammation and AHR, blocking anti-
bodies and control antibodies were given by i.n. administration. Mice received 
50 μg of anti–IL-6R antibodies (rat anti-mouse; Chugai Pharmaceutical Inc.); 
control IgG (rat anti-mouse, Sigma-Aldrich; rat IgG1 isotype control, R&D 
Systems) or gp130-Fc (obtained from K.J. Kallen, University of Kiel, or R&D 
Systems) by i.n. administration on days 25–27. The antibody was given 30 
minutes before the i.n. OVA challenge. On day 28, airway plethysmography 
was performed followed by BAL, as described below.
Additional experiments were performed to assess the effect of anti–IL-6R 
antibody treatment i.p. before the first i.p. sensitization with OVA. In 
this set of experiments, mice were treated with an additional dose of 
anti–IL-6R antibody i.p. on day 0 (1 mg of anti–IL-6R antibodies) or IgG 
as control antibodies. All mice were housed in ventilated cages equipped 
with microisolator lids. All experiments were undertaken with approved 
license (number 177-07-991-32) from the Ethical Committee of the 
Region Rheinland-Pfalz (Mainz, Germany).
Assessment of airway reactivity by invasive body plethysmography. AHR in mice 
was evaluated by using an invasive, whole-body plethysmograph, as previ-
ously described (51–53). Lung resistance (RL) was measured in untreated, 
OVA-sensitized mice and control mice as well as in IgG-, anti–IL-6R anti-
body–, or fusion protein gp130-Fc–treated OVA-sensitized mice, as described 
previously (29). In brief, dose response curves to MCh were obtained in 
anesthetized mice after administering increasing doses of intravenous MCh 
(33–1,000 μg/kg). Data were expressed as mean values of RL ± SEM.
Collection and analysis of BAL. Twenty-four hours after the last i.n. chal-
lenge with either OVA or saline, BAL of the right lung was performed with 
0.75 ml saline 4 times. Total BALF was collected and cells were stained with 
trypan blue and counted using a 50 μl aliquot. Samples were centrifuged 
at 680 g for 5 minutes, and cell pellets were resuspended in 1 ml PBS. Cyto-
spins were made by centrifugation at 22.86 g for 5 minutes. Eosinophils 
were detected by staining according to May-Grünwald-Giemsa. The cyto-
spins were analyzed with an Olympus microscope, using a ×40 objective. 
The supernatants were frozen and subsequently analyzed by ELISA.
Isolation and analysis of lung CD4+ T cells. Lungs were removed from mice, 
transported in RPMI 1640 medium (with NaHCO3, glutamine tested for 
endotoxin; Biochrom AG), and cut into small pieces (1–2 mm2) with a for-
ceps. Tissue pieces were suspended in Dulbecco’s PBS (5 ml per lung) con-
taining 300 U/ml of collagenase type II (Worthington Biochemical Corp.) 
and 0.001% DNase (Roche Diagnostics). The suspension was incubated at 
37°C for 1 hour with constant shaking. The digest was filtered through a 
70-μm nucleopore filter to remove tissue fragments, centrifuged (300 g, 10 
minutes), and the cell pellet washed once with RPMI 1640, 100 units/ml 
penicillin, and 100 μg/ml streptomycin. Erythrocytes were removed from 
lung cell suspension by hypotonic lysis in ammonium chloride and potas-
sium chloride (ACK) buffer. After 2 washes in PBS, the cell pellet was resus-
pended in MACS buffer (PBS/EDTA with 0.5% BSA; Sigma-Aldrich). The 
CD4+ lung T cells were directly purified from isolated lung cell suspension 
by incubation at 4°C for 15 minutes with 10 μl of anti-mouse CD4 L3T4 
microbeads per 107 total lung cells and positively sorted in a multiparam-
eter magnetic cell sorter system (MACS; Miltenyi Biotech). After 3 washes in 
complete medium, the CD4-positive cells were cultured with plate-bound or 
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soluble (as indicated) anti-CD3 antibodies (CD3 clone 145-2C11, 5 μg/ml; 
BD Biosciences — Pharmingen) for 24 hours at a density of 106 cells/ml. The 
supernatant was analyzed for cytokine production by the BD Cytometric 
Bead Array System (BD Biosciences — Clontech) or ELISA.
Isolation of CD4+CD25+ cells from the lung. In additional experiments, the 
resulting CD4+ lung cells (purity 97%) were further separated by cell sorting 
into CD4+CD25+ and CD4+CD25– T cells. Briefly, isolated lung CD4+ T cells 
from BALB/c OVA-sensitized and -challenged (untreated) in vivo, anti–IL-6R 
antibody–treated, and IgG-treated mice were stained with 1 μg CD25-PE/ 
1 × 106 (Clone PC61; BD Biosciences) cells at 4°C for 30 minutes in the dark. 
Cells were then washed once in PBS and kept on ice. CD4+CD25+ cells were 
sorted on a BD FACSVantage SE System, and analysis was done with Cell 
Quest Pro software (BD Biosciences). Dead cells and debris were excluded 
from data analysis through appropriate forward scatter channel and SSC gat-
ing. For each sample, 20,000 events were collected. Markers and regions were 
set according to control staining. In 3 experiments performed either in dupli-
cated or triplicated conditions, sorted CD4+CD25+ lung cells (105 cells/well) 
or CD4+CD25– lung cells (105 cells/well) were cultured overnight with 2 μg/
ml of soluble anti-CD3 antibodies (BD Biosciences — Pharmingen). Super-
natants were then collected from cell suspensions, and IL-10 and TGF-β 
were measured by ELISA. During sorting we also measured the number of 
CD4+CD25+ cells isolated per group. In additional experiments, we isolated 
CD4+CD25+ cells from the lung as described below for the spleen.
Functional studies of CD4+CD25+ lung cells. In 3 independent experiments, 
CD4+CD25+ lung cells were purified after staining isolated CD4+ lung T 
cells with CD25-PE antibody. This was followed by incubation with anti-PE 
beads and immunomagnetic separation. CD4+CD25+ lung cells (105 cells/
well) or CD4+CD25– lung cells (105 cells/well) were then cocultured with 
CFSE-labeled (Molecular Probes Inc.) target primary CD4+ spleen cells (105 
cells/well) isolated from untreated mice and antigen-presenting cells (A20 
a murine B lymphoma cell line; 104 cells/well) in the presence of soluble 
anti-CD3 antibodies (2.5 μg/ml) overnight. After 20 hours, the starting 
levels of incorporated fluorescence was recorded (M1). The proliferation 
of the target spleen CD4+(CFSE+) cells was determined as the percentage of 
daughter cells that would reach generation M5 or M6. Two to 3 pools with 
2 lungs per pool were analyzed for each experimental group.
Functional studies on spleen CD4+CD25+ cells after IL-6 or anti–IL-6R antibody 
treatment. To perform functional studies on CD4+CD25+ cells, we isolated 
CD4+CD25+ spleen cells, as described below, from 7-week-old BALB/c mice. 
In each experiment, we isolated CD4+CD25+ cells from 12 mice and per-
formed functional studies on CD4+CD25+ cells incubated overnight with 
IL-6 (20 ng/ml) either alone, with 10 μg/ml of anti–IL-6R antibodies, or 
with 10 μg/ml of IgG normal mouse control antibodies.
Then the question arose as to whether anti–IL-6R antibody treatment 
would influence cytokine release induced by IL-6 in CD4+CD25+ and 
CD4+CD25– cells. To study this possibility, we incubated either CD4+CD25+ 
or CD4+CD25– cells overnight with medium alone or with medium and IL-6 
(20 ng/ml) alone or with IL-6 and 10 μg/ml of anti–IL-6R antibodies in the 
presence of soluble anti-CD3 antibodies (2.5 μg/μl). On the following day, 
we collected supernatants and measured IL-10 and TGF-β by ELISA.
pSTAT-3 immunostaining of CD4+CD25+ spleen cells. Fifty-thousand 
CD4+CD25+ or CD4+CD25– spleen cells were incubated for 30 minutes 
with IL-6 (20 ng/ml) alone or with 10 μg/ml of anti–IL-6R antibodies in the 
presence of soluble anti-CD3 antibodies (2.5 μg/μl) in duplicate. After that, 
cells were frozen for detection of pSTAT-3 activation. For immunodection 
of pSTAT-3, cells were fixed in 2% PFA in PBS for 10 minutes and washed 
twice in PBS. Cells were then permeabilized for 4 minutes in permeabiliza-
tion buffer (0.2% Triton X-100 in PBS) and washed twice in TBS buffer (0.05 
M Tris hydrochloride). After 40 minutes incubation in blocking buffer (3% 
BSA, 0.05% Tween 20 in TBS), the rabbit polyclonal anti–pSTAT-3 (Tyr705) 
antibody (Cell Signaling Technology) was applied (1:50) in blocking buffer 
and incubated overnight at 4°C. Detection of positive cells was performed 
after cells were incubated with a biotinylated goat anti-rabbit antibody (Vec-
tor Laboratories Inc.; 1:200 in blocking buffer) for 30 minutes. Finally the 
Cy2-streptavidine (1:500 in PBS) was added, followed by incubation for 60 
minutes, then washing in PBS. Cells were analyzed with an inverted fluores-
cence microscope (Olympus) at both ×200 and ×400 magnifications.
Reconstitution of Rag1–/– mice with CD4+CD25+ and CD4+CD25– cells. To 
demonstrate that isolated CD4+CD25+ cells would be able to inhibit the 
development of the asthmatic reaction, CD4+CD25+ T cells were isolated 
from the spleen of OVA-senstitized, IgG- or anti–IL-6R antibody–treated 
mice as described below. Briefly, CD4+ spleen cells were isolated by positive 
magnetic selection according to the manufacturer’s instructions (Dynal 
Biotech; 107 Dynabeads CD4-L3T4/ml; 25 μl beads for 2.5 × 106 cells) for 
20 minutes at 4°C under shaking conditions. Afterwards, the CD4 beads 
were detached by using mouse CD4 DETACHaBEAD (Dynal Biotech). 
Briefly, 10 μl of DETACHaBEAD were incubated with 106 CD4+ T cells 
under rotating conditions for 45 minutes at room temperature. The result-
ing CD4+ lung T cells were incubated with 10 μl (1 μg) of anti–CD25-PE/ 
1 × 106 (Clone 7D4; BD Biosciences) cells at 4°C for 20 minutes in the 
dark. Cells were then washed once in PBS/EDTA/0.5% BSA and kept on 
ice. CD4+CD25+ cells were isolated with a kit (CD25 Microbead Kit, mouse; 
Miltenyi Biotec) by immunomagnetic isolation after incubation with anti-
PE magnetic beads. Sorted CD4+CD25+spleen cells (5 × 105 cells/mouse) 
or CD4+CD25– cells (5 × 105 cells/mouse) were separately injected i.p. 
in Rag1–/– mice previously aerosolized once with 1% OVA aerosol for 30 
minutes. Specifically, mice received i.p. either unlabeled CD4+CD25– cells 
(5 × 105 cells/mouse) from OVA-sensitized and -challenged mice treated 
i.n. with IgG control antibodies or CD4+CD25+ cells (5 × 105 cells/mouse) 
from OVA-sensitized and -challenged and IgG- or anti–IL-6R antibody–
treated mice. Next all mice were injected i.p. with 5 × 105 of CFSE-labeled 
CD4+CD25– derived from OVA-sensitized and -challenged mice treated i.n. 
with a control antibody IgG. The next 3 days after reconstitution, mice 
were aerosolized with 1% OVA, and 24 hours later BALF was performed 
and lungs stored at –80°C for analysis of CFSE labeling. For CFSE analy-
sis, paraffin slides were fixed in 2% PFA in PBS for 10 minutes and washed 
twice in PBS, mounted in an aqueous mounting medium (Vector Labora-
tories Inc.), and analyzed at ×400 with an Olympus IX70 microscope con-
nected to a digital camera (Sony Power HAD, 3CCD color video camera 
DXC-950P; Sony Corp.). Images were then transferred to a computer and 
analyzed through a soft imaging system analysis program.
Histological assessment of airway inflammation. Images were imported (×20; 
image width: 640 μm each) into Photoshop (version 7.0; Adobe Systems Inc.). 
The hematoxylin-stained darker nuclei around the bronchi were counted 
around a mask layered over the image. A 100-μm margin was then placed 
around the bronchus and the mean gray level (corresponding to the num-
ber of cells, as determined using a calibration curve) determined using the 
histogram command in Photoshop. Then the rest of the image was quanti-
fied in the same way, with the exclusion of large empty areas (corresponding 
to vessels and/or other neighboring bronchi). This background gray level 
corresponded to the cellular density of the lung parenchyma and was then 
subtracted from the peribronchial cell density in each image. This was per-
formed for every image (5 < n > 12 per group). The results are reported as 
the subtracted peribronchiolar area (corresponding to the inflammatory cell 
infiltrate around the bronchi) and are given as mean ± SD and SEM.
Isolation of RNA from CD4+ T cells. Sorted and cultured CD4+CD25+ and 
CD4+CD25– lung cells were immediately frozen after culture until RNA 
was isolated following the manufacturer’s instructions (RNeasy Micro Kit; 
QIAGEN). Briefly, cells were disrupted directly in the plastic wells by add-
ing 350 μl of lysis buffer containing β-mercaptoethanol. Cells were then 
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homogenized with a rotor for 30 seconds and mixed with an equal volume 
(350 μl) of 70% ethanol. The samples were then applied to an RNeasy Min-
Elute Spin Column (QIAGEN) in a 2 ml collection tube. Closed tubes were 
then centrifuged for 15 seconds at 8,000 g. The column was washed several 
times, and the eluate was collected by applying 14 μl of RNAse-free water to 
the column. RNA concentration was determined using a densitometer.
RT-PCR from CD4+ lung cells. Six μl of total RNA from either CD4+CD25+ 
or CD4+CD25– cells was then reverse transcribed by use of the RevertAid 
1st Strand cDNA Synthesis Kit for RT-PCR (M-MuLV RT; MBI Fermentas 
GmbH). The resulting cDNA was then used as a template for the PCR. 
For Foxp3 analysis we used the following primers: 5′-GGCGAAAGTG-
GCAGAGAGGTAT-3′ and 5′-AAGACCCCAGTGGCAGCAGAA-3′; the 
RNA for the IL-6R α chain was amplified by using 5′-ACACACTGGTTCT-
GAGGGAC-3′ sense and 5′-TACCACAAGGTTGGCAGGTG-3′ antisense 
primers; T-bet antisense 5′-TGCCCCGCTTCCTCTCCAACCAA-3′, sense 
5′-TGCCTGCAGTGCTTCTAACA-3′; GATA-3 antisense CTGGAGGAG-
GAACGCTAATG-3′, sense GGTTGAAGGAGCTGCTCTTG-3′. The prim-
ers for actin were: 5′-TGACGGGGTCACCCACACTGTGCCCATCTA-3′ 
and 5′-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3′. The PCR pro-
gram was as follows: 93°C for 3 minutes, 32 cycles of 93°C for 30 seconds, 
60°C (56°C for GATA-3) for 30 seconds (1 minute for T-bet), and 72°C for 
1 minute followed by a final extension period of 10 minutes at 72°C. PCR 
products were analyzed on 1.5% agarose gels.
Real-time analysis of Foxp3 mRNA. To eliminate amplifications from con-
taminating genomic DNA, the following primers were designed to span 
an intron/exon boundary and thus to anneal specifically to cDNA: Foxp3 
forward 5′-CTTATCCGATGGGCCATCCTGGAAG-3′, reverse 5′-TTCCAG-
GTGGCGGGGTGGTTTCTG-3′; HGPRT forward 5′-GTTGGATACAGGC-
CAGACTTTGTTG-3′, reverse 5′-GAGGGTAGGCTGGCCTATAGGCT-3′.
Real-time analysis of Foxp3 mRNA was performed on an iCycler (Bio-Rad 
Laboratories) using the IQ SYBR Green Supermix (Bio-Rad Laboratories). 
After normalization of the data according to the expression of HGPRT 
mRNA, relative expression levels of Foxp3 mRNA were calculated.
CBA. CD4+ T cells isolated from the lungs of untreated or anti–IL-6R anti-
body– or IgG-treated, OVA-sensitized mice were incubated overnight in the 
presence of anti-CD3 antibodies. The supernatants were then analyzed by 
FACS using CBA (Mouse Inflammation Kit; BD Biosciences — Pharmingen) 
in accordance with the manufacturer’s instructions. Briefly, 6 bead popula-
tions with distinct fluorescence intensities were coated with capture anti-
bodies specific for IL-6, IL-10, MCP-1, IFN-γ, TNF-α, and IL-12p70 proteins. 
The 6 bead populations were mixed together to form the CBA, which was 
resolved in the FL3 channel of a flow cytometer. The capture beads, PE-con-
jugated detection antibodies, and recombinant standards or test samples 
were incubated together to form sandwich complexes. Following acquisi-
tion of samples data using a flow cytometer, the sample results were gener-
ated in graphical and tabular format using CBA Analysis Software (BD).
ELISA. Mouse IL-4, IL-5, IL-6, IFN-γ, and IL-10 were detected using 
a specific sandwich ELISA (OptEIA; BD Biosciences — Pharmingen). 
Murine IL-13 was detected using an ELISA kit (R&D Systems). TGF-β 
analysis was performed by using purified rat anti-mouse, anti-human, 
and anti-pig TGF-β1 as capture antibody (BD Biosciences — Pharmingen) 
and biotinylated rat anti-mouse, anti-human, and anti-pig TGF-β1 (BD 
Biosciences — Pharmingen) polyclonal antibody. Recombinant TGF-β was 
purchased from R&D. To activate TGF-β, 200-μl samples were pretreated 
with 10 μl of 1N HCl for 30 minutes at 37°C. Samples were then neutral-
ized by adding 10 μl of 1 N NaOH.
Protein extraction and Western blot analysis. Tissue proteins were extracted as 
previously described (39). Briefly, tissue was homogenized in PBS and pro-
tein extracted in the presence of protease inhibitors (6.75% aprotinin, 312 
μg/ml trypsin inhibitor) and detergent (Nonidet). Protein concentrations 
were determined by spectrophotometry with the Bio-Rad protein assay 
(Bio-Rad Laboratories). Equal amounts of protein extract were added to the 
electrophoresis sample buffer. After being boiled, proteins were separated by 
10% or 15% SDS-PAGE, transferred to nitrocellulose membranes, and incu-
bated in blocking solution (5% milk in PBS/0.05% Tween 20) for 1 hour at 
room temperature; they were subsequently exposed to 1 μg/ml of antibod-
ies against GATA-3 and ERK-2 (Santa Cruz Biotechnology Inc.) in block-
ing solution. Specific binding was visualized with the ECL Western Blotting 
Detection System (Amersham Biosciences) according to the manufacturer’s 
instructions after 1-hour incubation with the corresponding secondary HPR-
conjugated antibody (1:2000 in blocking solution; Amersham Biosciences).
Statistical analysis. Differences were evaluated for significance (P < 0.05) 
by the Student’s 2-tailed t test for independent events (Microsoft Excel, 
version 2000; Microsoft Corp.). The coefficient of correlations was cal-
culated by statistical analysis using Microsoft Excel. Data are given as 
mean values ± SEM. For the analysis of RL data, the multivariate analysis 
MANOVA (Wilks’ Lambda) was used.
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